|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q1 FY2023
As of Mar 31, 2023
|
Q3 FY2022
As of Sep 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | ||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||
| Total current assets | ||||||||||||||||
| Marketable securities held in Trust Account | ||||||||||||||||
| Interest receivable in cash and marketable securities held in the Trust Account | ||||||||||||||||
| Right-of-use assets, net | ||||||||||||||||
| Total assets | ||||||||||||||||
| Current liabilities: | ||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||
| Related party payables | ||||||||||||||||
| Related Party | ||||||||||||||||
| Total related party payables | ||||||||||||||||
| Due to related party | ||||||||||||||||
| Advance from target company for de-SPAC transaction | ||||||||||||||||
| Franchise tax payable | ||||||||||||||||
| Income tax payable | ||||||||||||||||
| Excise tax payable | ||||||||||||||||
| Notes payable - bridge loan | ||||||||||||||||
| Related Party | ||||||||||||||||
| Total notes payable - bridge loan | ||||||||||||||||
| Convertible notes payable - related party | ||||||||||||||||
| Related Party | ||||||||||||||||
| Total convertible notes payable - related party | ||||||||||||||||
| Short-term lease liabilities | ||||||||||||||||
| Total current liabilities | ||||||||||||||||
| Deferred underwriting commissions | ||||||||||||||||
| Deferred underwriting commissions | ||||||||||||||||
| Long-term lease liabilities | ||||||||||||||||
| Total liabilities | ||||||||||||||||
| Commitments and Contingencies (Note 4) | ||||||||||||||||
| Common stock subject to possible redemption, 36,771 shares at redemption value of $11.03 and $11.03 per share as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||
| Stockholders' deficit: | ||||||||||||||||
| Common stock, par value $0.0001, 200,000,000 shares authorized; 2,082,825 shares issued and outstanding as of June 30, 2026 and December 31, 2025 respectively | ||||||||||||||||
| Accumulated deficit | ||||||||||||||||
| Total stockholders' deficit | ||||||||||||||||
| Total liabilities, redeemable common stock and stockholders' deficit | ||||||||||||||||
Loading...
